Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
=== Environmental === Environmental biotechnology includes various disciplines that play an essential role in reducing environmental waste and providing environmentally safe processes, such as biofiltration and biodegradation. The environment can be affected by biotechnologies, both positively and adversely. Vallero and others have argued that the difference between beneficial biotechnology (e.g., bioremediation is to clean up an oil spill or hazard chemical leak) versus the adverse effects stemming from biotechnological enterprises (e.g., flow of genetic material from transgenic organisms into wild strains) can be seen as applications and implications, respectively. Cleaning up environmental wastes is an example of an application of environmental biotechnology; whereas loss of biodiversity or loss of containment of a harmful microbe are examples of environmental implications of biotechnology. Many cities have installed CityTrees, which use biotechnology to filter pollutants from urban atmospheres.
Traditional additive solutions are hypotonic, although experiments with next-generation additive solutions suggest that an alkali pH in combination with low chloride concentrations may be able to prolong the red blood cell viability. Leucocyte depletion of blood components, including red blood cell concentrates, is increasingly becoming standard practise; in many of the high-income countries of the world, 100% of the red blood cell supply is already being leucocyte depleted. Leucocyte depletion, usually by a leucocyte filter included in the blood bag system, is an efficient yet relatively cheap way of reducing the risk of transfusion reactions. Leucocyte depletion is most commonly performed as an integrated processing step, as bedside filtration is considered a less efficient method.
=== Hypopituitarism === An adequate cortisol response is defined as a rise to greater than 550 nmol/L. Patients with impaired cortisol responses (less than 550 but greater than 400 nmol/L) may only need steroid cover for major illnesses or stresses. An adequate GH response occurs with an absolute response exceeding 20 mU/L.
=== Hypoaldosteronism === An ACTH stimulation test for aldosterone can help in determining the cause of hypoaldosteronism, with a low aldosterone response indicating a primary hypoaldosteronism of the adrenals, while a large response indicating a secondary hypoaldosteronism. The most common cause of this condition (and related symptoms) is Addison's disease; it is typically treated by fludrocortisone, which has a much longer persistence (1 day) in the bloodstream.
Sources: en.wikipedia.org
== Mass spectrometry == The tropylium ion is frequently encountered in mass spectrometry in the form of a signal at m/z = 91 and is used in mass spectrum analysis. This fragment is often found for aromatic compounds containing a benzyl unit. Upon ionization, the benzyl fragment forms a cation (PhCH+2), which rearranges to the highly stable tropylium cation (C7H+7).
Backed by the Kampuchean United Front for National Salvation, an organization of Khmer pro-Soviet Communists and Khmer Rouge defectors, Vietnam invaded Cambodia on 22 December 1978. The invasion succeeded in deposing Pol Pot, but the new state struggled to gain international recognition beyond the Soviet Bloc sphere. Despite the international outcry at the Pol Pot regime's gross human rights violations, representatives of the Khmer Rouge were allowed to be seated in the UN General Assembly, with strong support from China, the Western powers, and the member countries of ASEAN. Following the destruction of the Khmer Rouge, the national reconstruction of Cambodia was hampered, and Vietnam suffered a punitive Chinese attack. Although unable to deter Vietnam from ousting Pol Pot, China demonstrated that its Cold War communist adversary, the Soviet Union, was unable to protect its Vietnamese ally. Former U.S. Secretary of State Henry Kissinger wrote that "China succeeded in exposing the limits of...[Soviet] strategic reach" and speculated that the desire to "compensate for their ineffectuality" contributed to the Soviets' decision to intervene in Afghanistan a year later. In the 1973 oil crisis, Organization of Petroleum Exporting Countries (OPEC) cut their petroleum output. This raised oil prices and hurt Western economies, but helped the Soviet Union by generating a huge flow of money from its oil sales.
=== Water location === Dr. Alain Gachet founded Radar Technologies International (RTI) in 1999 to use satellite generated data to identify probable locations of precious metals and during its use found it could also detect water. The system developed with this data, WATEX, uses about 80 percent of its data inputs from publicly available NASA information. This free information allowed RTI to develop the WATEX system to successfully locate water sources, such as in 2004 at refugee camps during the War in Darfur.
== See also == List of Award of Garden Merit tulips Tulip period – Period in Ottoman historyPages displaying short descriptions of redirect targets Dahlia – Genus of flowering plants in the daisy family
== History == Herodotus notes that cherry juice was consumed by the Argippaeans, either fresh or mixed with milk. Cherry juice was also drunk by ancient Romans. In the late 19th century, cherry juice was not produced in the United States, and was imported from Germany. The imported juice was used by wholesale liquor and drug companies, as well as soda producers. Drug companies typically used the juice to produce syrups for soda water, and liquor companies used it to produce cherry brandy, cherry bounce and liqueurs. German-imported cherry juice was fortified with alcohol to prevent the juice from fermenting, which would spoil it. During this time, juice produced in Magdeburg, Germany from black cherries grown in the area was typically exported to the U.S.
Sources: en.wikipedia.org
International Chemical Safety Card 0275 (gas) International Chemical Safety Card 0695 (solution) NIOSH Pocket Guide to Chemical Hazards. "#0293". National Institute for Occupational Safety and Health (NIOSH). Entry for "Formaldehyde" on the Australian National Pollutant Inventory Formaldehyde from ChemSub Online Prevention guide—Formaldehyde in the Workplace (PDF) from the IRSST Formaldehyde from the National Institute for Occupational Safety and Health IPCS Health and Safety Guide 57: Formaldehyde IPCS Environmental Health Criteria 89: Formaldehyde SIDS Initial Assessment Report for Formaldehyde from the Organisation for Economic Co-operation and Development (OECD) Formaldehyde in the Pesticide Properties DataBase (PPDB)
One of their most challenging scenes made, was the opening scene of the first episode for which they depicted the nearly total destruction of New York City. For the creation of the effects, every department had to contribute to produce high-quality hyper-real 2D and 3D elements and detailed set extensions combined with matte paintings. Also, several shots involving dozens of high-resolution render layers, though it posed data management challenge.
== Awards and honours == 1998 Founders Award for Excellence from the Canadian College of Medical Geneticists. 1996 Honoured by Human Genome Organization at a special presentation in Heidelberg. 1996 Fellow of the American Association for the Advancement of Science. Fellow of the Canadian College of Medical Geneticists.
On 3 August 2023, Move Forward MP Nakhonchai Khunnarong resigned over his criminal record, but Move Forward held Rayong 3rd district after Phongsathorn Sornpetchnarin won the by-election. On 28 September, Move Forward MP for Phitsanulok 1st district Padipat Suntiphada left the party to retain his position as First Deputy Speaker of the House of Representatives, which the opposition party is barred from holding. As sitting MPs are required to be members of political parties, Padipat joined the Fair Party on 31 October increasing that party's total seats to two. In November 2023, amid a sexual assault scandal, Move Forward expelled two MPs: Wuttiphong Thonglour of Prachinburi on 1 November and Chaiyamparwaan Munphianchit of Bangkok on 7 November. By the end of November, Chaiyamparwaan joined the Thai Progress Party as its only MP whilst Wuttiphong joined the Chart Pattana Party and increased its number of MPs to three. On 30 August 2023, the sole MP and leader of the Thai Liberal Party, Sereepisuth Temeeyaves, resigned his seat and was replaced by Mangkorn Yontrakul also from the Thai Liberal. On 7 August 2024, Move Forward was dissolved by the Constitutional Court over the party's campaign to amend Thailand's lèse-majesté laws. The dissolution accompanied five sitting party-list MPs receiving 10-year bans from politics: Pita Limjaroenrat, Chaithawat Tulathon, Apichart Sirisunthon, Bencha Saengchantra and Suthep U-on. As party-list seats, no by-elections were held and the five seats remained vacant.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.